NASDAQ:ONCY Oncolytics Biotech (ONCY) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free ONCY Stock Alerts $1.09 +0.01 (+0.93%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$1.06▼$1.1050-Day Range$0.92▼$1.1652-Week Range$0.88▼$3.39Volume219,102 shsAverage Volume367,270 shsMarket Capitalization$82.21 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Oncolytics Biotech alerts: Email Address Oncolytics Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside267.0% Upside$4.00 Price TargetShort InterestHealthy1.23% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.32) to ($0.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.12 out of 5 starsMedical Sector772nd out of 908 stocksPharmaceutical Preparations Industry359th out of 423 stocks 3.5 Analyst's Opinion Consensus RatingOncolytics Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOncolytics Biotech has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.23% of the outstanding shares of Oncolytics Biotech have been sold short.Short Interest Ratio / Days to CoverOncolytics Biotech has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncolytics Biotech has recently decreased by 0.28%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldOncolytics Biotech does not currently pay a dividend.Dividend GrowthOncolytics Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONCY. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Oncolytics Biotech this week, compared to 1 article on an average week.Search Interest7 people have searched for ONCY on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Oncolytics Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -56% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of Oncolytics Biotech is held by insiders.Percentage Held by InstitutionsOnly 6.82% of the stock of Oncolytics Biotech is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Oncolytics Biotech are expected to decrease in the coming year, from ($0.32) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncolytics Biotech is -3.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncolytics Biotech is -3.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncolytics Biotech has a P/B Ratio of 4.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Oncolytics Biotech Stock (NASDAQ:ONCY)Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Read More ONCY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONCY Stock News HeadlinesApril 25, 2024 | finanznachrichten.deOncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual MeetingApril 25, 2024 | prnewswire.comOncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual MeetingApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 21, 2024 | theglobeandmail.comClosing Bell: Oncolytics Bio up on Friday (ONC)April 13, 2024 | theglobeandmail.comBiotech Breakthroughs Spearhead Fight Against Rising Breast Cancer CasesApril 11, 2024 | finanznachrichten.deUSA News Group: Biotech Innovations Paving the Way in Breast Cancer FightApril 11, 2024 | msn.comOncolytics seeking FDA meeting to discuss registration-enabling studyApril 11, 2024 | prnewswire.comOncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDAApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.March 14, 2024 | finanznachrichten.deUSA News Group: Biotech's Role in Addressing the Pancreatic Cancer EmergencyMarch 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Oncolytics Biotech Amidst Promising Pipeline and Advancements in Cancer Treatment TrialsMarch 10, 2024 | finance.yahoo.comOncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | markets.businessinsider.comBuy Rating Affirmed on Oncolytics Biotech Amid Progress and Strategic Clinical TrialsMarch 8, 2024 | finanznachrichten.deOncolytics Biotech Inc.: Oncolytics Biotech Reports Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsMarch 7, 2024 | prnewswire.comOncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsMarch 5, 2024 | prnewswire.comOncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCANFebruary 28, 2024 | prnewswire.comOncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer ConferenceFebruary 15, 2024 | finance.yahoo.comHere's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn SituationFebruary 15, 2024 | baystreet.caOncolytics Biotech IncFebruary 14, 2024 | finanznachrichten.deOncolytics Biotech Inc.: Oncolytics Biotech Initiates Enrollment Expansion of GOBLET Anal Cancer CohortFebruary 14, 2024 | finanznachrichten.deOncolytics Biotech® Inc.: Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer CohortFebruary 14, 2024 | finance.yahoo.comOncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer CohortFebruary 14, 2024 | prnewswire.comOncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer CohortJanuary 23, 2024 | msn.comOutlook stock rallies on private placement, FDA study agreementJanuary 9, 2024 | finanznachrichten.deOncolytics Biotech® Inc.: Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of DirectorsJanuary 9, 2024 | finance.yahoo.comOncolytics Biotech® Appoints Patricia S. Andrews to its Board of DirectorsJanuary 4, 2024 | finanznachrichten.deOncolytics Biotech® Inc.: Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024See More Headlines Receive ONCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/26/2024Next Earnings (Estimated)5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ONCY CUSIPN/A CIK1129928 Webwww.oncolyticsbiotech.com Phone(403) 670-7377Fax403-283-0858Employees29Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$5.00 Low Stock Price Target$3.00 Potential Upside/Downside+267.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,560,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-105.97% Return on Assets-72.80% Debt Debt-to-Equity RatioN/A Current Ratio9.01 Quick Ratio9.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book4.04Miscellaneous Outstanding Shares75,420,000Free Float75,345,000Market Cap$82.21 million OptionableNot Optionable Beta1.93 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Matthew C. Coffey M.B.A.Ph.D., President, CEO & DirectorMr. Kirk J. Look C.A.CA, Chief Financial OfficerDr. Thomas C. Heineman M.D.Ph.D., Chief Medical OfficerMs. Allison Hagerman P.Eng.P.M.P., Vice President of Product DevelopmentMs. Amy Goodowitz Levin B.S.N.R.N., Vice President of Clinical OperationsJon PattonDirector of Investor Relations & CommunicationMr. John Mark Lievonen BBAC.M., FCA, LLD, MBA, ConsultantMore ExecutivesKey CompetitorsInflaRxNASDAQ:IFRXAileron TherapeuticsNASDAQ:ALRNMarinus PharmaceuticalsNASDAQ:MRNSAffimedNASDAQ:AFMDLeap TherapeuticsNASDAQ:LPTXView All Competitors ONCY Stock Analysis - Frequently Asked Questions Should I buy or sell Oncolytics Biotech stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ONCY shares. View ONCY analyst ratings or view top-rated stocks. What is Oncolytics Biotech's stock price target for 2024? 3 brokers have issued twelve-month price objectives for Oncolytics Biotech's shares. Their ONCY share price targets range from $3.00 to $5.00. On average, they expect the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 267.0% from the stock's current price. View analysts price targets for ONCY or view top-rated stocks among Wall Street analysts. How have ONCY shares performed in 2024? Oncolytics Biotech's stock was trading at $1.35 at the start of the year. Since then, ONCY stock has decreased by 19.3% and is now trading at $1.09. View the best growth stocks for 2024 here. When is Oncolytics Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024. View our ONCY earnings forecast. How were Oncolytics Biotech's earnings last quarter? Oncolytics Biotech Inc. (NASDAQ:ONCY) released its quarterly earnings results on Thursday, March, 7th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.07. What is Brad Thompson's approval rating as Oncolytics Biotech's CEO? 2 employees have rated Oncolytics Biotech Chief Executive Officer Brad Thompson on Glassdoor.com. Brad Thompson has an approval rating of 56% among the company's employees. This puts Brad Thompson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Oncolytics Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), KushCo (KSHB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT). How do I buy shares of Oncolytics Biotech? Shares of ONCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ONCY) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
